Developer docs
API playgroundTry for free, no card

Search company profiles

AllStripes

Full company profile

uuid0000ixn

Namestring
AllStripes
Websiteurl
allstripes.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

AllStripes is a San Francisco-based healthcare technology company founded in 2017 that operates a B2B2C platform enabling rare disease patients to contribute their de-identified longitudinal health records to support biopharma research and clinical trials. The platform's core function is collecting, de-identifying, and organizing medical records contributed by patients, then making aggregated, de-identified datasets available to biopharmaceutical companies conducting rare disease research. Patients serve as the data-contributing side, while biopharmaceutical companies serve as the data-buying side for research, clinical trial design, and recruitment support. The company specializes narrowly in rare diseases, where small global patient populations make data assembly otherwise difficult.

The business model is data monetization: AllStripes licenses access to its proprietary rare-disease dataset to biopharma customers rather than charging patients. Pricing is not publicly disclosed and no customer logos have been revealed. AllStripes has raised approximately $67 million across four funding rounds through August 2021, with the $50 million Series B led by Lux Capital and including strategic healthcare investors McKesson Ventures and Medidata alongside Spark Capital, Maveron, Jazz Venture Partners, Bossa Invest, Trajectory Ventures, Garuda Ventures, Village Global, and Shasta Ventures. The headcount is reported in the 51–100 range.

Following the Series B, AllStripes has publicly committed to expanding its rare disease research programs and operations across additional countries. The company is led by co-founder and CEO Nancy Yu, with Leo Vand serving as VP of Engineering and Joe Walsh as a Vice President. No AI/ML capabilities, patents, regulatory actions, mergers, acquisitions, or leadership changes beyond the named team are disclosed in the available source material.

Short descriptiontext

AllStripes is a San Francisco healthcare technology company that operates a B2B2C platform enabling rare disease patients to contribute de-identified health records, then licenses the aggregated dataset to biopharmaceutical companies for research and clinical trial support.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease research, patient health records, clinical trial data, biopharma data licensing, de-identified health data
Industry3 codes
PRIMARYHLAJAJAE
Disease Registries (Cancer, Immunization, Rare Disease, etc.)
Healthcare & Life Sciences/Public Health, Government & Regulators/Health Statistics, Vital Records & Population Health Analytics
SECONDARYHLACAHAH
Patient Registries & Chronic Disease Registry Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLACABAH
Record Locator Services (RLS) & Longitudinal Record Aggregation
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
NAICS code1 code
  • Medical Laboratories621511
SIC code2 codes
  • Services-Health Services8000
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Healthcare Data Platform
Revenue model1 record
1Data Access/Licensing to Biopharma
TypeData Monetisation
Description

AllStripes generates revenue by enabling access to de-identified patient health records for biopharma companies conducting rare disease research and clinical trials. Patients contribute their health records which are then made available (in de-identified form) to pharmaceutical researchers.

medcitynews.com
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

AllStripes operates a healthcare technology platform that enables rare disease patients to share their de-identified health records and then licenses access to this aggregated, longitudinal dataset to biopharmaceutical companies to support rare disease research, clinical trial design, and patient recruitment.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AllStripes offers a healthcare technology platform that enables patients to share their de-identified health records to support biopharma research and clinical trials focused on rare diseases.

Product and service1 record
1AllStripes Platform
CategoryHealthcare Data Platform
Description

A healthcare technology platform that enables rare disease patients to contribute their de-identified health records and provides biopharmaceutical companies with access to longitudinal patient data for rare disease research and clinical trials.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Healthcare data and analytics platform primarily serving health systems and providers. Indirectly comparable as a healthcare data platform; less direct overlap since its buyer base skews provider rather than biopharma.

TypeDirect peer
Description

Patient-mediated platform that aggregates medical records from multiple points of care and partners with biopharma and academic centers on research studies, including rare disease. Closest direct competitor with the same B2B2C patient-to-biopharma data model.

TypeBroad incumbent
Description

Roche-owned real-world evidence and EHR data platform serving oncology biopharma. Competes for biopharma RWD budgets and clinical trial data needs, though its primary focus is oncology rather than rare disease.

TypeBroad incumbent
Description

Global clinical research services and real-world data giant offering biopharma data, analytics, and trial solutions. Overlaps with AllStripes on real-world data licensing and clinical trial enablement, but at much greater scale and breadth.

TypeBroad incumbent
Description

Dassault Systèmes subsidiary providing clinical trial technology, data, and analytics to biopharma. Also a strategic investor in AllStripes. Competes in the broader clinical-trial data and digital trial enablement space.

TypeDirect peer
Description

Patient-reported outcomes and real-world data platform (now under Optum) that aggregates patient experiences to support research. Highly comparable patient-to-researcher data-sharing model, though historically weighted toward self-reported rather than EHR data.

TypeEmerging player
Description

Non-profit/cross-stakeholder data platform purpose-built for collecting and sharing rare disease patient data with researchers. Operates in AllStripes' rare-disease niche but with a non-profit/registry-leaning model.

TypeEmerging player
Description

Longitudinal patient data platform that consolidates EHR, genomics, and wearable data for research and clinical trials. Comparable in aggregating multi-source patient records for biopharma, though broader than rare disease.

TypeBroad incumbent
Description

Alphabet-owned health technology and data company running clinical research, real-world evidence, and precision medicine programs. Competes in the broader patient-data-for-research category with far greater capital and infrastructure.

TypeEmerging player
Description

Global health research network aggregating EHR data from participating hospitals for clinical trial design, patient recruitment, and real-world evidence. Comparable EHR-to-biopharma data flow, though provider-mediated rather than patient-mediated.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AllStripes

Healthcare Data Platformallstripes.com

AllStripes is a San Francisco healthcare technology company that operates a B2B2C platform enabling rare disease patients to contribute de-identified health records, then licenses the aggregated dataset to biopharmaceutical companies for research and clinical trial support.

What AllStripes does

AllStripes is a San Francisco-based healthcare technology company founded in 2017 that operates a B2B2C platform enabling rare disease patients to contribute their de-identified longitudinal health records to support biopharma research and clinical trials. The platform's core function is collecting, de-identifying, and organizing medical records contributed by patients, then making aggregated, de-identified datasets available to biopharmaceutical companies conducting rare disease research. Patients serve as the data-contributing side, while biopharmaceutical companies serve as the data-buying side for research, clinical trial design, and recruitment support. The company specializes narrowly in rare diseases, where small global patient populations make data assembly otherwise difficult.

The business model is data monetization: AllStripes licenses access to its proprietary rare-disease dataset to biopharma customers rather than charging patients. Pricing is not publicly disclosed and no customer logos have been revealed. AllStripes has raised approximately $67 million across four funding rounds through August 2021, with the $50 million Series B led by Lux Capital and including strategic healthcare investors McKesson Ventures and Medidata alongside Spark Capital, Maveron, Jazz Venture Partners, Bossa Invest, Trajectory Ventures, Garuda Ventures, Village Global, and Shasta Ventures. The headcount is reported in the 51–100 range.

Following the Series B, AllStripes has publicly committed to expanding its rare disease research programs and operations across additional countries. The company is led by co-founder and CEO Nancy Yu, with Leo Vand serving as VP of Engineering and Joe Walsh as a Vice President. No AI/ML capabilities, patents, regulatory actions, mergers, acquisitions, or leadership changes beyond the named team are disclosed in the available source material.

AllStripes firmographics

Firmographics
Name
AllStripes
Website
https://allstripes.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
AllStripes is a San Francisco healthcare technology company that operates a B2B2C platform enabling rare disease patients to contribute de-identified health records, then licenses the aggregated dataset to biopharmaceutical companies for research and clinical trial support.
Ownership category
akta.pro rank

AllStripes industry classification

Industry
Product category
Healthcare Data Platform
NAICS
Medical Laboratories (621511)
SIC
Services-Health Services (8000), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLAJAJAE
Disease Registries (Cancer, Immunization, Rare Disease, etc.)
Healthcare & Life Sciences/Public Health, Government & Regulators/Health Statistics, Vital Records & Population Health Analytics
SECONDARYHLACAHAH
Patient Registries & Chronic Disease Registry Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLACABAH
Record Locator Services (RLS) & Longitudinal Record Aggregation
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability

Keywords

  • Rare disease research
  • Patient health records
  • Clinical trial data
  • Biopharma data licensing
  • De-identified health data

Where AllStripes is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AllStripes business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Data Access/Licensing to Biopharma: AllStripes generates revenue by enabling access to de-identified patient health records for biopharma companies conducting rare disease research and clinical trials. Patients contribute their health records which are then made available (in de-identified form) to pharmaceutical researchers.

AllStripes product offering

Product offering

Core offering

AllStripes operates a healthcare technology platform that enables rare disease patients to share their de-identified health records and then licenses access to this aggregated, longitudinal dataset to biopharmaceutical companies to support rare disease research, clinical trial design, and patient recruitment.

Product overview

AllStripes offers a healthcare technology platform that enables patients to share their de-identified health records to support biopharma research and clinical trials focused on rare diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • AllStripes Platform A healthcare technology platform that enables rare disease patients to contribute their de-identified health records and provides biopharmaceutical companies with access to longitudinal patient data for rare disease research and clinical trials.

Companies that use AllStripes

Customer profile

Segments2 records

Ideal customer profiles2 records

AllStripes technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

AllStripes partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

AllStripes competitors and assessment

Company assessment

Others

  • Health Catalyst: Healthcare data and analytics platform primarily serving health systems and providers. Indirectly comparable as a healthcare data platform; less direct overlap since its buyer base skews provider rather than biopharma.

Direct peers

  • PicnicHealth: Patient-mediated platform that aggregates medical records from multiple points of care and partners with biopharma and academic centers on research studies, including rare disease. Closest direct competitor with the same B2B2C patient-to-biopharma data model.
  • PatientsLikeMe: Patient-reported outcomes and real-world data platform (now under Optum) that aggregates patient experiences to support research. Highly comparable patient-to-researcher data-sharing model, though historically weighted toward self-reported rather than EHR data.

Broad incumbents

  • Flatiron Health: Roche-owned real-world evidence and EHR data platform serving oncology biopharma. Competes for biopharma RWD budgets and clinical trial data needs, though its primary focus is oncology rather than rare disease.
  • IQVIA: Global clinical research services and real-world data giant offering biopharma data, analytics, and trial solutions. Overlaps with AllStripes on real-world data licensing and clinical trial enablement, but at much greater scale and breadth.
  • Medidata Solutions: Dassault Systèmes subsidiary providing clinical trial technology, data, and analytics to biopharma. Also a strategic investor in AllStripes. Competes in the broader clinical-trial data and digital trial enablement space.
  • Verily (Alphabet): Alphabet-owned health technology and data company running clinical research, real-world evidence, and precision medicine programs. Competes in the broader patient-data-for-research category with far greater capital and infrastructure.

Emerging players

  • RARE-X: Non-profit/cross-stakeholder data platform purpose-built for collecting and sharing rare disease patient data with researchers. Operates in AllStripes' rare-disease niche but with a non-profit/registry-leaning model.
  • Seqster: Longitudinal patient data platform that consolidates EHR, genomics, and wearable data for research and clinical trials. Comparable in aggregating multi-source patient records for biopharma, though broader than rare disease.
  • TriNetX: Global health research network aggregating EHR data from participating hospitals for clinical trial design, patient recruitment, and real-world evidence. Comparable EHR-to-biopharma data flow, though provider-mediated rather than patient-mediated.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

AllStripes social profiles

Digital presence

AllStripes financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AllStripes leadership team

Management profile

Number of profiles

Profiles3 records

AllStripes funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AllStripes M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AllStripes

What does AllStripes do?

AllStripes operates a healthcare technology platform that enables rare disease patients to share their de-identified health records and then licenses access to this aggregated, longitudinal dataset to biopharmaceutical companies to support rare disease research, clinical trial design, and patient recruitment.

Is AllStripes a public or private company?

AllStripes is a private company. It is classified as venture growth investor backed and is currently operating.

When was AllStripes founded?

AllStripes was founded in 2017. It employs 1 to 10 people.

Where is AllStripes based?

AllStripes is headquartered in San Francisco, United States, in the North America region.

How does AllStripes make money?

One revenue line is on record: data Access/Licensing to Biopharma.

Who are AllStripes's main competitors?

Health Catalyst is listed as an others. Direct peers are PicnicHealth and PatientsLikeMe. Broad incumbents are Flatiron Health, IQVIA, Medidata Solutions and Verily (Alphabet). Emerging players are RARE-X, Seqster and TriNetX.

Does AllStripes have an API?

No public API is recorded for AllStripes.

What industry is AllStripes in?

AllStripes's product category is Healthcare Data Platform. Its primary akta.pro industry code is HLAJAJAE, Disease Registries (Cancer, Immunization, Rare Disease, etc.), with a secondary code of HLACAHAH, Patient Registries & Chronic Disease Registry Analytics. Its NAICS code is 621511 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Healthcare IT TodayPicnicHealth Acquires AllStripes, Fortifying its Role as the Leader in Patient-Centered Healthcare Evidence GenerationPicnicHealth acquired AllStripes, a platform for generating evidence about rare diseases, to strengthen its patient-centered evidence generation. The deal follows AllStripes' $50 million Series B and PicnicHealth's $60 million Series C, with financial terms undisclosed. The companies aim to expand solutions for life sciences customers.FinSMEsPicnicHealth Acquires AllStripesPicnicHealth acquired AllStripes, a San Francisco-based platform for generating evidence about rare diseases. The deal amount was not disclosed. AllStripes, founded in 2017, has raised $50m in Series B funding, while PicnicHealth raised $60m in Series C.HIT ConsultantM&A: PicnicHealth Acquires Rare Disease Platform AllStripesPicnicHealth acquired AllStripes, a healthcare technology company focused on rare disease research and drug development. Financial terms were not disclosed. The acquisition aims to expand PicnicHealth's ability to curate clinical data and patient-reported outcomes for biopharma customers.American City Business JournalsMedical records company PicnicHealth buys AllStripesPicnicHealth acquired AllStripes, a San Francisco medical records company, with terms undisclosed. About 20 of AllStripes' 40 employees joined PicnicHealth, which now has about 120. CEO Noga Leviner said the deal was driven by a tough funding environment.Business Wire BlogPicnicHealth Acquires AllStripes, Fortifying its Role as the Leader in Patient-Centered Healthcare Evidence GenerationPicnicHealth acquired AllStripes, a platform for generating evidence about rare diseases. The deal combines their patient engagement models to expand clinical research and registry development. Financial terms were not disclosed.PicnichealthPicnicHealth acquires AllStripes to advance medical researchPicnicHealth has acquired AllStripes, a healthcare technology company specializing in rare disease research and patient data platforms. This strategic consolidation aims to expand PicnicHealth's capabilities in generating clinical evidence for life sciences customers by leveraging AllStripes' patient community relationships. The financial terms of the transaction were not disclosed.Business Wire BlogAllStripes Announces $50 Million Series B Financing to Advance Global Rare Disease ResearchAllStripes, a healthcare technology company focused on rare disease research, announced it completed a $50 million Series B round led by Lux Capital, with JAZZ Venture Partners, Spark Capital, Medidata Solutions, McKesson Ventures and Maveron joining. The funds will launch 100 new rare disease research programs, expand operations, and enhance data automation. The company partners with over 30 patient advocacy organizations across 40 conditions and more than 3,000 users.MedCity NewsAllStripes raises $50 million to support rare disease researchSan Francisco-based AllStripes, a platform letting patients store and share health records for rare disease research, closed a $50 million Series B round led by Lux Capital. The company, founded in 2017 by Nancy Yu and Onno Faber, has worked with 3,000 users and 30 patient advocacy organizations, including Novartis and the University of Pennsylvania's Orphan Disease Center. It plans to launch 100 rare disease research programs and expand into more countries.FinSMEsAllStripes Raises $50M in Series B FinancingAllStripes, a healthcare technology company based in San Francisco, raised $50 million in Series B financing led by Lux Capital with participation from JAZZ Venture Partners, Spark Capital, and others. The company plans to utilize the funds to launch 100 new rare disease research programs, expand its global operational presence, and enhance its platform capabilities for life sciences offerings.